Biostock interviews Chordate Medical’s CSO Jan Hermansson about the inclusion of the first patient in the company’s open pilot study PM009. The purpose of the study is to evaluate the effectiveness of Chordate’s migraine treatment, Ozilia, in patients who do not respond to treatment with CGRP inhibitors and other treatment options.
“Of course, we hope that many patients will have a significant reduction in their migraine and days with headache. Every patient who reports improvement will be considered a success, especially since other alternatives have not had the desired effect […] The number of migraine and headache days is measured daily via an electronic diary. Even a reduction of 2 – 3 migraine days per month is considered a significant improvement for the patient. Since the study is open, we can continuously follow the patients and see the trends”, says Jan Hermansson to Biostock.
